Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma

NCT07746960 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-Resectable

Interventions

DRUG: Intravenous chemotherapy with the Ralox regimen combined with Anlotinib and Penpulimab

Sponsor

Nanfang Hospital, Southern Medical University